HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Two-week topical treatment with Essaven gel in patients with diabetic microangiopathy--a placebo-controlled, randomized study.

Abstract
The involvement of the microcirculation in diabetic microangiopathy (DM) causes of severe incapacitation and ulceration. DM is characterized by a diffuse increase in flux, reduction in venoarteriolar response, associated with increased permeability resulting in edema and altered function of microlymphatics. In DM, skin PO2 is decreased and CO2 increased. In this condition capillary exchanges are altered and nutritional alterations eventually lead to skin lesions and ulcers. The aim of this randomized, placebo-controlled study was to evaluate the effect of local (foot) treatment with Essaven gel (EG) in 35 subjects with DM and neuropathy and localized, small (< 0.5 cm in maximum diameter) ulcers treated for 2 weeks. Measurements of laser Doppler (LDF) flux, PO2, and PCO2 in standardized conditions showed positive microcirculatory changes (a significant decrease of the abnormally increased flux and CO2 while PO2 increased) in the active EG group. Changes in the control group were not significant. In the placebo group variations were limited (mainly associated with skin manipulation and gel application). In conclusion, local treatment for 2 weeks with standardized application of EG acutely improves the microcirculation in subjects with DM and small ulceration.
AuthorsM R Cesarone, L Incandela, G Belcaro, M T De Sanctis, A Ricci, M Griffin
JournalAngiology (Angiology) Vol. 52 Suppl 3 Pg. S43-8 (Dec 2001) ISSN: 0003-3197 [Print] United States
PMID11775648 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Drug Combinations
  • Fibrinolytic Agents
  • Phospholipids
  • Escin
  • Essaven Gel
  • Heparin
Topics
  • Administration, Topical
  • Diabetic Angiopathies (drug therapy)
  • Diabetic Foot (drug therapy)
  • Double-Blind Method
  • Drug Combinations
  • Escin (administration & dosage)
  • Female
  • Fibrinolytic Agents (administration & dosage)
  • Heparin (administration & dosage)
  • Humans
  • Male
  • Microcirculation (drug effects)
  • Middle Aged
  • Phospholipids (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: